the aid library

LIST OPTIONS

Filter

3239

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (157)

View PDF (179)

Ethical considerations in HIV prevention trials

World Health Organization WHO; UNAIDS (2021) C_WHO

UNAIDS and the World Health Organization have published this updated guidance on ethical considerations in HIV prevention trials. The new guidance is the result of a year-long process that saw more than 80 experts and members of the public give inputs and is published 21 years after the first editio... more

External Link

Nigeria: Good Clinical Practice Guidelines

National Agency for Food and Drugs Administration and Control (NAFDAC) (2016) C2

Download (428)

View PDF (812)

Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies

Alipanah N, Jarlsberg L et al. (2018) CC

We systematically reviewed Medline as well as the references of published review articles for relevant studies of adherence to multidrug treatment of both drug-susceptible and drug-resistant TB through February 3, 2018. We included randomized controlled trials (RCTs) as well as prospective and retro... more

Download (124)

View PDF (148)

Nota Conceitual para o Consórcio do África CDC para Ensaios Clínicos para Vacina da COVID-19 (CONCVACT)

African Union; Africa CDC Centres for Disease Control and Prevention (2020) C1

A Estratégia Conjunta Continental Africana para a COVID-19 é sustentada pela necessidade de limitar a transmissão, prevenir mortes e reduzir os danos associados. A participação das nações africanas em ensaios clínicos é um passo essencial para garantir que sejam gerados dados suficientes so... more

Download (215)

View PDF (159)

Consortium du Centre Africain pour le Contrôle et la Prévention des Maladies (CACM) pour les essais cliniques sur le vaccin contre la COVID-19 (CONCVACT)

African Union; Africa CDC Centres for Disease Control and Prevention (2020) C1

La stratégie continentale commune africaine pour COVID-19 est sous-tendue par la nécessité de limiter la transmission, de prévenir les décès et de réduire les dommages associés. La participation des nations africaines aux essais cliniques est une étape essentielle pour garantir la productio... more

Download (134)

View PDF (131)

Effects of BCG on COVID-19 — based on information as of 25 December 2020

World Health Organization WHO (2020) C_WHO

WHO Regional Office for Africa

Effets de la vaccination par le BCG sur la COVID-19 — sur la base des informations disponibles au 25 décembre 2020

Organisation Mondiale de la Santé, Bureau régional de l'OMS pour l'Afrique (2020) C_WHO

Efeitos da vacina BCG na COVID-19 — com base na informação disponível a 25 de Dezembro de 2020

Organização Mundial da Saúde. Escritório Regional para a África (2020) C_WHO

Download (608)

View PDF (1203)

Ghana: GUIDELINES FOR REPORTING ADVERSE REACTION

Food and Drugs Authority (FDA), Ghana (2016) C2

Document No. : FDA/SMC/SMD/GL-RAR/2013/01

Download (378)

View PDF (647)

Male Circumcision and HIV in Lesotho: Is the Relationship Real or Spurious? Analysis of the 2009 Demographic and Health Survey

Makatjane, T. J., T. Hlabana, and E. M. Letete Rockville, Maryland, USA: ICF International (2016) C2

DHS Working Papers No. 125

External Link

The Top COVID-19 Vaccine Myths Spreading Online

Gregory, J. NewsGuard (2021) CC

Scientists and researchers managed to produce vaccines to protect against COVID-19. Vaccine candidates have recently been approved in some countries and are in the approval process in others, yet misinformation about the safety and effects of any future vaccine is already threatening its rollout. In... more

Download (932)

View PDF (1267)

Ghana: Public Health Act

Government of Ghana (2012) C1

Act 851 | AN ACT to revise and consolidate the law relating to public health to prevent disease, promote, safeguard, maintain and protect the health of humans and animals and to provide for related matters.

Download (150)

View PDF (168)

Clinical Guidelines: Antiretroviral drugs for HIV prevention - Chapter 3

World Health Organization (2019) C_WHO

Accessed: 27.11.2019

Download (88)

View PDF (135)

Ten Clinical Tips on COVID-19 for Healthcare Providers Involved in Patient Care

Centers for Disease Control and Prevention CDC (2020) C_CDC

External Link

Clinical Updates in Reproductive Health

Alice Mark IPAS (2016) C1

The publication is designed to provide Ipas staff, trainers, partners and other health-care providers with access to up-to-date, evidence-based recommendations. In general, the recommendations are the same as those in the World Health Organization’s 2012 Safe Abortion: Technical and Policy Guidanc... more

Download (1733)

View PDF (1499)

Field Trials of Health Interventions: A Toolbox

Peter G. Smith, Richard H. Morrow, and David A. Ross (2015)

This version of Field Trials of Health Interventions includes seven new chapters on conducting systematic literature reviews, trial governance, preliminary studies and pilot testing, budgeting and accounting, intervention costing and economic analysis, and Phase IV studies. Before new interventions... more

Download (351)

View PDF (561)

Money & Microbes: Strengthening clinical research capacity to prevent epidemics

International Vaccines Task Force (IVTF) (2018) C1

Robust clinical research capacity in low- and middle-income countries is key to stemming the spread of epidemics, according to a new report from the International Vaccines Task Force (IVTF). The report lays out how to develop the political support, financing and coordination required to build this c... more

External Link

Clinical and public health implications of acute and early HIV detection and treatment: a scoping review

Rutstein, S.E., J. Ananworanich, S. Fidler, et al. Journal of the International AIDS Society (2017) CC

Rutstein SE et al. Journal of the International AIDS Society 2017, 20:21579 http://www.jiasociety.org/index.php/jias/article/view/21579 | http://dx.doi.org/10.7448/IAS.20.1.21579

Download (178)

View PDF (170)

National clinical guideline for stroke

Royal College of Physicians, London (2016) C1